US 12,268,741 B2
Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ROR1)
Andreia Costa, Seattle, WA (US); Rupesh Amin, Seattle, WA (US); Jenna Bailey, Seattle, WA (US); Samriti Bedi, Newcastle, WA (US); Brian Belmont, Seattle, WA (US); Aye Chen, Seattle, WA (US); Stephen Jacob Goldfless, Seattle, WA (US); Eric Jeffery, Seattle, WA (US); Yue Jiang, Seattle, WA (US); Yeonjoo Oh, Seattle, WA (US); Madeline Williams, Seattle, WA (US); Collin Hauskins, Seattle, WA (US); and Catherine Sierra, Seattle, WA (US)
Assigned to Juno Therapeutics, Inc., Seattle, WA (US)
Appl. No. 17/421,365
Filed by Juno Therapeutics, Inc., Seattle, WA (US)
PCT Filed Jan. 28, 2020, PCT No. PCT/US2020/015489
§ 371(c)(1), (2) Date Jul. 7, 2021,
PCT Pub. No. WO2020/160050, PCT Pub. Date Aug. 6, 2020.
Claims priority of provisional application 62/798,456, filed on Jan. 29, 2019.
Prior Publication US 2022/0096651 A1, Mar. 31, 2022
Int. Cl. A61K 47/68 (2017.01); A61K 35/17 (2015.01); A61K 39/00 (2006.01); A61K 39/395 (2006.01); A61P 35/00 (2006.01); C12N 5/0783 (2010.01); C12N 5/10 (2006.01); C12N 15/62 (2006.01); C12N 15/63 (2006.01)
CPC A61K 39/39558 (2013.01) [A61K 39/4611 (2023.05); A61K 39/4631 (2023.05); A61K 39/464402 (2023.05); A61K 47/6851 (2017.08); A61P 35/00 (2018.01); C12N 5/0636 (2013.01); C12N 5/10 (2013.01); C12N 15/62 (2013.01); C12N 15/63 (2013.01); A61K 2239/31 (2023.05); A61K 2239/38 (2023.05); A61K 2239/48 (2023.05); A61K 2239/49 (2023.05); A61K 2239/55 (2023.05)] 49 Claims
 
1. An anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) antibody or antigen-binding fragment thereof comprising: a heavy chain variable (VH) region and a light chain variable (VL) region, wherein:
the VH region comprises a heavy chain complementarity determining region 1 (CDR-H1), a heavy chain complementarity determining region 2 (CDR-H2) and a heavy chain complementarity determining region 3 (CDR-H3) contained within SEQ ID NO: 112, and the VL region comprises a light chain complementarity determining region 1 (CDR-L1), a light chain complementarity determining region 2 (CDR-L2) and a light chain complementarity determining region 3 (CDR-L3) contained within SEQ ID NO:115;
the VH region comprises a CDR-H1, a CDR-H2 and a CDR-H3 contained within SEQ ID NO: 121, and the VL region comprises a CDR-L1, a CDR-L2 and a CDR-L3 contained within SEQ ID: NO 124;
the VH region comprises a CDR-H1, a CDR-H2 and a CDR-H3 contained within SEQ ID NO: 103, and the VL region comprises a CDR-L1, a CDR-L2 and a CDR-L3 contained within SEQ ID: NO 106; or
the VH region comprises a CDR-H1, a CDR-H2 and a CDR-H3 contained within SEQ ID NO: 130, and the VL region comprises a CDR-L1, a CDR-L2 and a CDR-L3 contained within SEQ ID: NO 106.